Abstract
The different long-chain fatty acid oxidation defects present with similar heterogeneous clinical phenotypes of different severity. Organs mainly affected comprise the heart, liver, and skeletal muscles. All symptoms are reversible with sufficient energy supply. In some long-chain fatty acid oxidation defects, disease-specific symptoms occur. Only in disorders of the mitochondrial trifunctional protein (TFP) complex, including long-chain 3-hydroxyacyl-coenzyme A (CoA) dehydrogenase (LCHAD) deficiency, neuropathy and retinopathy develop that are progressive and irreversible despite current treatment measures. In most long-chain fatty acid oxidation defects, no clear genotype–phenotype correlation exists due to molecular heterogeneity. However, some isolated mutations have been identified to be associated with only mild phenotypes, e.g., the V243A mutation in very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. LCHAD deficiency is due to the prevalent homozygous 1528G>C mutation and presents with heterogeneous clinical phenotypes, suggesting the importance of other environmental and genetic factors. For some disorders, it was shown that residual enzyme activity measured in fibroblasts or lymphocytes correlated with severity of clinical phenotype. Implementation of newborn screening has significantly reduced morbidity and mortality of long-chain fatty acid oxidation defects. However, the severest forms of TFP deficiency are still highly associated with neonatal death. Newborn screening also identifies a great number of mildly affected patients who may never develop clinical symptoms throughout life. However, later-onset exercise-induced myopathic symptoms remain characteristic clinical features of long-chain fatty acid oxidation defects. Disease prevalence has increased with newborn screening.
Similar content being viewed by others
Abbreviations
- ACAD9:
-
Acyl-CoA dehydrogenase 9
- CACT:
-
Carnitine acylcarnitine translocase
- CPT1:
-
Carnitine palmitoyl-CoA transferase 1
- CPT2:
-
Carnitine palmitoyl-CoA transferase 2
- GAII:
-
Glutaric aciduria type II (= electron transfer defect = MAD deficiency)
- LCAD:
-
Long-chain acyl-CoA dehydrogenase
- LCHAD:
-
Long-chain 3-hydroxyacyl-CoA dehydrogenase
- LCHADD:
-
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
- LKAT:
-
Long-chain 3-ketoacyl-CoA thiolase
- MAD:
-
Multiple acyl-CoA dehydrogenase
- MCAD:
-
Medium-chain acyl-CoA dehydrogenase
- mTFP:
-
Mitochondrial trifunctional protein
- OCTN2:
-
Organic cation carnitine transporter 2
- VLCAD:
-
Very-long-chain acyl-CoA dehydrogenase
- VLCADD:
-
Very-long-chain acyl-CoA dehydrogenase deficiency
References
Andresen BS, Olpin S, Poorthuis BJ et al (1999) Clear correlation of genotype with disease phenotype in very long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet 64:479–494
Arnold GL, Van Hove J, Freedenberg D et al (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96:85–90
Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J (2004) Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 25:495–520
den Boer ME, Wanders RJ, Morris AA, IJlst L, Heymans HS, Wijburg FA (2002) Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics 109:99–104
den Boer ME, Dionisi-Vici C, Chakrapani A, van Thuijl AO, Wanders RJ, Wijburg FA (2003) Mitochondrial trifunctional protein deficiency: a severe fatty acid oxidation disorder with cardiac and neurologic involvement. J Pediatr 142:684–689
Ensenauer R, He M, Willard JM et al (2005) Human acyl-CoA dehydrogenase-9 plays a novel role in the mitochondrial beta-oxidation of unsaturated fatty acids. J Biol Chem 280:32309–32316
Gillingham MB, Weleber RG, Neuringer M et al (2005) Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency. Mol Genet Metab 86:124–133
Goetzman ES, Wang Y, He M, Mohsen AW, Ninness BK, Vockley J (2007) Expression and characterization of mutations in human very long-chain acyl-CoA dehydrogenase using a prokaryotic system. Mol Genet Metab 91:138–147
Gregersen N, Andresen BS, Corydon MJ et al (2001) Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum Mutat 18:169–189
Ibdah JA (2006) Acute fatty liver of pregnancy: an update on pathogenesis and clinical implications. World J Gastroenterol 12:7397–7404, Review
Illsinger S, Lücke T, Peter M (2008) Carnitine-palmitoyltransferase 2 deficiency: novel mutations and relevance of newborn screening. Am J Med Genet 146A:2925–2928
Laforêt P, Acquaviva-Bourdain C, Rigal O et al (2009) Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord 19:324–329
Liebig M, Schymik I, Mueller M et al (2006) Neonatal screening for very long-chain acyl-coA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels. Pediatrics 118:1065–1069
Maier EM, Pongratz J, Muntau AC et al (2009) Validation of MCADD newborn screening. Clin Genet 76:179–187
Mütze S, Ahillen I, Rudnik-Schoeneborn S et al (2007) Neither maternal nor fetal mutation (E474Q) in the alpha-subunit of the trifunctional protein is frequent in pregnancies complicated by HELLP syndrome. J Perinat Med; 35:76–78
Oey NA, Ruiter JP, Ijlst L et al (2006) Acyl-CoA dehydrogenase 9 (ACAD 9) is the long-chain acyl-CoA dehydrogenase in human embryonic and fetal brain. Biochem Biophys Res Commun 21(346):33–37
Olsen RK, Olpin SE, Andresen BS et al (2007) ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 130:2045–2054
Sander J, Sander S, Steuerwald U et al (2005) Neonatal screening for defects of the mitochondrial trifunctional protein. Mol Genet Metab 85:108–114
Schuler AM, Wood PA (2002) Mouse models for disorders of mitochondrial fatty acid beta-oxidation. ILAR J 43:57–65
Spiekerkoetter U, Sykut-Cegielska (2007) Prognosis and treatment of LCHAD deficiency. 39th EMG workshop results, pp 16–19. Publication of workshop results, printed by Milupa GmbH, Bahnstrasse 14-30, 61381 Friedrichsdorf, Germany. ISBN 987-3-9811868-0-2. www.Milupa-Metabolics.com
Spiekerkoetter U, Huener G, Baykal T et al (2003a) Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2. J Inherit Metab Dis 26:613–615
Spiekerkoetter U, Sun B, Zytkovicz T, Wanders R, Strauss AW, Wendel U (2003b) MS/MS-based newborn and family screening detects asymptomatic patients with very long-chain acyl-CoA dehydrogenase deficiency. J Pediatr 143:335–342
Spiekerkoetter U, Tenenbaum T, Heusch A, Wendel U (2003c) Cardiomyopathy and pericardial effusion in infancy point to a fatty acid beta-oxidation defect after exclusion of an underlying infection. Pediatr Cardiol 24:295–297
Spiekerkoetter U, Sun B, Khuchua Z, Bennett MJ, Strauss AW (2003d) Molecular and phenotypic heterogeneity in mitochondrial trifunctional protein deficiency due to beta-subunit mutations. Hum Mutat 21:598–607
Spiekerkoetter U, Khuchua Z, Yue Z, Bennett MJ, Strauss AW (2004a) General mitochondrial trifunctional protein (TFP) deficiency as a result of either alpha-or beta-subunit mutations exhibits similar phenotypes because mutations in either subunit alter TFP complex expression and subunit turnover. Pediatr Res 55:190–196
Spiekerkoetter U, Khuchua Z, Yue Z, Strauss AW (2004b) The early-onset phenotype of mitochondrial trifunctional protein deficiency: a lethal disorder with multiple tissue involvement. J Inherit Metab Dis 27:294–296
Spiekerkoetter U, Bennett MJ, Ben-Zeev B, Strauss AW, Tein I (2004c) Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve 29:66–72
Spiekerkoetter U, Mueller M, Cloppenburg E et al (2008) Intrauterine cardiomyopathy and cardiac mitochondrial proliferation in mitochondrial trifunctional protein (TFP) deficiency. Mol Genet Metab 94:428–430
Spiekerkoetter U, Lindner M, Santer R et al (2009) Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis 32:488–497
Tein I, Demaugre F, Bonnefont JP, Saudubray JM (1989) Normal muscle CPT1 and CPT2 activities in hepatic presentation patients with CPT1 deficiency in fibroblasts. Tissue specific isoforms of CPT1? J Neurol Sci 92:229–245
ter Veld F, Mueller M, Kramer S et al (2009) A novel tandem mass spectrometry method for rapid confirmation of medium-and very long-chain acyl-CoA dehydrogenase deficiency in newborns. PLoS One 4(7):e6449
Tyni T, Kivelä T, Lappi M, Summanen P, Nikoskelainen E, Pihko H (1998) Ophthalmologic findings in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation: a new type of hereditary metabolic chorioretinopathy. Ophthalmology 105:810–824
Vockley J (2008) Glutaric aciduria type 2 and newborn screening: commentary. Mol Genet Metab 93:5–6
Wanders RJA, Vreken P, Den Boer MEJ et al (1999) Disorders of mitochondrial fatty acyl-CoA β-oxidation. J Inherit Metab Dis 22:442–487
Wilcken B, Haas M, Joy P et al (2007) Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369:37–42
Zhang J, Zhang W, Zou D et al (2002) Cloning and functional characterization of ACAD-9, a novel member of human acyl-CoA dehydrogenase family. Biochem Biophys Res Commun 297:1033–1042
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by: Verena Peters
Competing interest: None declared.
Presented at the Fulda-Symposium “Fatty acid oxidation: clinical, biochemical and molecular aspects”, 12–14 November 2008
Rights and permissions
About this article
Cite this article
Spiekerkoetter, U. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis 33, 527–532 (2010). https://doi.org/10.1007/s10545-010-9090-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-010-9090-x